<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17161</article-id><article-id pub-id-type="doi">10.7554/eLife.17161</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Pro-death NMDA receptor signaling is promoted by the GluN2B C-terminus independently of DAPK1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-57106"><name><surname>McQueen</surname><given-names>Jamie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57107"><name><surname>Ryan</surname><given-names>Tomas J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57108"><name><surname>McKay</surname><given-names>Sean</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57109"><name><surname>Marwick</surname><given-names>Katie FM</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-91675"><name><surname>Baxter</surname><given-names>Paul E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57110"><name><surname>Carpanini</surname><given-names>Sarah M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-93124"><name><surname>Wishart</surname><given-names>Thomas M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57111"><name><surname>Gillingwater</surname><given-names>Thomas H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57112"><name><surname>Manson</surname><given-names>Jean C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57113"><name><surname>Wyllie</surname><given-names>David JA</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4957-6049</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15945"><name><surname>Grant</surname><given-names>Seth GN</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8732-8735</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-57114"><name><surname>McColl</surname><given-names>Barry</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0521-9656</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57115"><name><surname>Komiyama</surname><given-names>Noboru</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-17729"><name><surname>Hardingham</surname><given-names>Giles E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7629-5314</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">UK Dementia Research Institute</institution>, <institution>Edinburgh Medical School, University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">School of Biochemistry and Immunology</institution>, <institution>Trinity College Dublin</institution>, <addr-line><named-content content-type="city">Dublin</named-content></addr-line>, <country>Ireland</country></aff><aff id="aff3"><institution content-type="dept">Centre for Discovery Brain Sciences</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">The Roslin Institute</institution>, <institution>University of Edinburgh</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">University of Edinburgh</institution>, <institution>The Roslin Institute</institution>, <addr-line><named-content content-type="city">Edinburgh</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution>Wellcome Trust Sanger Institute</institution>, <addr-line><named-content content-type="city">Hinxton</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-13593"><name><surname>Chao</surname><given-names>Moses V</given-names></name><role>Reviewing editor</role><aff><institution>New York University Langone Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Barry.McColl@roslin.ed.ac.uk</email> (BM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>Giles.Hardingham@ed.ac.uk</email> (GH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>07</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e17161</elocation-id><history><date date-type="received"><day>22</day><month>04</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>07</month><year>2017</year></date></history><permissions><copyright-statement>Â© 2017, McQueen et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>McQueen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-17161-v1.pdf"/><abstract><p>Aberrant NMDA receptor (NMDAR) activity contributes to several neurological disorders, but direct antagonism is poorly tolerated therapeutically. The GluN2B cytoplasmic C-terminal domain (CTD) represents an alternative therapeutic target since it potentiates excitotoxic signaling. The key GluN2B CTD-centred event in excitotoxicity is proposed to involve its phosphorylation at Ser-1303 by DAPK1, that is blocked by a neuroprotective cell-permeable peptide mimetic of the region. Contrary to this model, we find that excitotoxicity can proceed without increased Ser-1303 phosphorylation, and is unaffected by DAPK1 deficiency <italic>in vitro</italic> or following ischemia in vivo. Pharmacological analysis of the aforementioned neuroprotective peptide revealed that it acts in a sequence-independent manner as an open-channel NMDAR antagonist at or near the Mg<sup>2+</sup> site, due to its high net positive charge. Thus, GluN2B-driven excitotoxic signaling can proceed independently of DAPK1 or altered Ser-1303 phosphorylation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>WT088156</award-id><principal-award-recipient><name><surname>Hardingham</surname><given-names>Giles E</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MRC_G0902044</award-id><principal-award-recipient><name><surname>McQueen</surname><given-names>Jamie</given-names></name><name><surname>McKay</surname><given-names>Sean</given-names></name><name><surname>Baxter</surname><given-names>Paul E</given-names></name><name><surname>Hardingham</surname><given-names>Giles E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experiments using live animals were conducted under the authority of UK Home Office project and personal licences and adhered to regulations specified in the Animals (Scientific Procedures) Act (1986) and Directive 2010/63/EU and were approved by both The Roslin Institute's and the University of Edinburgh's Animal Welfare and Ethics Committees. Experimental design, analysis and reporting followed the ARRIVE guidelines (https://www.nc3rs.org.uk/arrive-guidelines) where possible. Animal experimentation: Animals used in this study were treated in accordance with UK Animal Scientific Procedures Act (1986) . The relevant Home Office project licences are P1351480E and 60/4407, and the use of genetically modified organisms approved by local committee reference SBMS 13_007.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-17161-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>